The confluence of nanotechnology and biotechnology provides significant commercial opportunities. By identifying, classifying and tracking firms with capabilities in both biotechnology and nanotechnology over time, we analyze the emergence and evolution of the global nanobiotechnology industry.Research in nanotechnology has expanded rapidly in the last 15 years, but the development of commercial products has been significantly slower [1][2][3] . One of the most promising areas for commercialization is the application of nanotechnology to biological processes [4][5][6] . This is due, in part, to the fact that it involves the confluence of two previously disparate research fieldsnanotechnology and biotechnology -and novel combinations of ideas and approaches are known to increase the opportunities for innovation 7,8 .The rate of increase in nanobiotechnology invention is well documented 9,10 . However, little is known about the commercialization of these inventions and the entry of firms into the field. For example, what types of companies have both biotechnology and nanotechnology capabilities, when and where did they develop them, and what applications are they targeting? And are these companies actually integrating nanotechnology with biotechnology? Here we explore the emergence of the global nanobiotechnology industry by identifying, tracking and analysing firms with capabilities in biotechnology and nanotechnology, and examining the degree to which they integrate their knowledge.
Entry and exit of nanobiotechnology firmsThrough longitudinal analysis and an extensive search and validation process, we identified 507 firms globally targeting human health that have both biotechnology and nanotechnology capabilities. We categorized our sample by firm type, location, and industry sub-sector. We then tracked the entry and exit of these firms, including mergers and acquisitions. Details on our methodology are available in the supplementary information accompanying this paper online.NOTE: This is the final author version (accepted manuscript) of: Maine, E., Thomas, V.J., Bliemel, M., Murira, A. and Utterback, J., (2014). The Emergence of the Nanobiotechnology Industry, Nature Nanotechnology, 9(1), 2-5. were already 10 multinational corporations with both biotechnology and nanotechnology capabilities (Fig. 1). (In fact, research areas such as liposomes, which are now considered to be within the realm of nanotechnology, have existed in polymer chemistry research since the 1960s.) Specific nanobiotechnology applications began to emerge in the early 1990s.As of 1999, the majority of the firms in the emerging nanobiotechnology sector were de novo firms, which we define as new ventures founded specifically to commercialize the opportunities arising from the confluence of biotechnology and nanotechnology. De novo firms rapidly increased in number between 1995 and 2007 ( Fig. 1), with a total of 215 entries during that time period. The timing of these entries is consistent with the claim that new ventures are more l...